Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 2Thrombocytopenia 1Myelodysplastic Syndromes 1Motor Activity 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 21fludarabine phosphate 13Cyclosporine 11Antilymphocyte Serum 11Peripheral Blood Stem Cell Transplantation 10Methotrexate 10Busulfan 10Cytarabine 9Filgrastim 8Radiotherapy 7Dexamethasone 7Whole-Body Irradiation 6Mycophenolic Acid 6Methylprednisolone 6Melphalan 6Exercise 6fludarabine 5Vincristine 5Daunorubicin 5Cord Blood Stem Cell Transplantation 5pegaspargase 4Rituximab 4Palliative Care 4Mercaptopurine 4Etoposide 4Early Intervention, Educational 4Blood Specimen Collection 4Asparaginase 4Alemtuzumab 4Thioguanine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Leukemia × Platelet Transfusion × Clear all
NCT01615146 2015-09-02

OPTIMAL

Ottawa Hospital Research Institute

Phase NA Terminated
9 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡